Welcome to our dedicated page for Assertio Holdings news (Ticker: ASRT), a resource for investors and traders seeking the latest updates and insights on Assertio Holdings stock.
Assertio Holdings, Inc. (NASDAQ: ASRT) generates a steady flow of news related to its role as a pharmaceutical company focused on oncology, neurology, and pain management. This news page aggregates company-issued press releases and other coverage so readers can follow developments that affect Assertio’s business and ASRT stock.
Recent communications emphasize Assertio’s commercial execution around Rolvedon, a long-acting G-CSF indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in certain adult cancer patients, and SYMPAZAN, an oral film formulation of clobazam approved for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome. News items include clinical trial readouts, such as a phase 1 study of same-day dosing of Rolvedon with chemotherapy, and real-world evidence studies describing how Sympazan is used in daily clinical practice.
Investors and observers will also find updates on financial results, guidance ranges, and strategic priorities, including portfolio focus on core growth assets, responses to generic competition for products like Indocin, and steps to streamline the corporate structure. Assertio’s announcements cover quarterly net product sales, adjusted EBITDA, and commentary on commercial performance, alongside information about investor conference participation and earnings calls.
Governance and capital markets developments appear in the news flow as well, such as leadership transitions at the chief executive level, the appointment of a President and Chief Operating Officer, and the implementation of a 1-for-15 reverse stock split to support Nasdaq listing compliance. Subsequent confirmation from Nasdaq that Assertio regained compliance with listing requirements is also communicated through press releases.
By reviewing the ASRT news feed, readers can track clinical data publications, operational updates, executive changes, supply and licensing agreements, and listing status disclosures that help explain how Assertio is executing its stated strategy in oncology, neurology, and pain management.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Assertio Holdings, Inc. (Nasdaq: ASRT) announced the release date for its first quarter 2023 financial results, which is set for May 9, 2023, after market close. Following this release, management will conduct a live webcast earnings conference call at 4:30 p.m. Eastern Time. Investors can access the call via the company's investor relations website. A replay will be available approximately two hours after the call concludes.
Assertio is a specialty pharmaceutical company focused on offering differentiated products to patients. It utilizes a non-personal promotional model and is actively building its commercial portfolio through existing products and potential acquisitions or licensing of approved products.
Assertio has announced a definitive agreement to acquire Spectrum Pharmaceuticals in an all-stock and contingent value rights transaction. Spectrum stockholders will receive 0.1783 shares of Assertio for each Spectrum share, representing an upfront value of $1.14 per share and a premium of 65% to Spectrum's latest closing price. Total potential consideration can reach $1.34 per share, with a premium of 94%. The transaction is expected to close in Q3 2023, resulting in Assertio stockholders owning approximately 65% and Spectrum stockholders approximately 35% of the combined entity. This acquisition is anticipated to be accretive to Assertio's adjusted EPS and operating cash flow in 2024, leveraging Spectrum's commercial capabilities and the ROLVEDON product to enhance market access.
Assertio Holdings, Inc. (Nasdaq: ASRT) has announced a $100,000 educational grant to the Lennox-Gastaut Syndrome (LGS) Foundation to support the launch of their 'About LGS Treatments Kits' aimed at assisting families affected by LGS. This initiative aims to provide crucial information regarding seizure treatments and management options for LGS patients aged two years and older, who are treated with SYMPAZAN (clobazam) oral film. SYMPAZAN is the only FDA-approved oral film formulation for adjunctive treatment of seizures linked to LGS. Assertio's initiative reflects its commitment to enhancing awareness and education around LGS, as emphasized by the company's CEO, Dan Peisert.
Assertio Holdings, Inc. (NASDAQ: ASRT) announced the granting of 20,542 restricted stock units (RSUs) and 24,018 stock options to two new employees effective April 3, 2023. This action complies with NASDAQ Listing Rule 5635(c)(4), intended as an inducement for their entry into employment. The options, priced at $6.11 per share, match the closing price of Assertio's stock on the grant date. The RSUs and options will vest equally over three years, starting from one year after the grant date. Assertio is a leading pharmaceutical company focusing on differentiated products across neurology, hospital, and pain/inflammation sectors, with growth through licensing, mergers, and acquisitions. Investors should note the forward-looking statements regarding future performance are subject to risks and uncertainties.
Assertio Holdings, Inc. (ASRT) reported a remarkable financial performance for Q4 and the full year 2022. Net product sales soared by 55% in Q4, reaching $49.9 million, and increased 42% for the full year, totaling $155.1 million. The company achieved a net income of $109.6 million, significantly up from a loss in 2021, driven by a substantial tax benefit. Adjusted EBITDA rose 108% to $101.6 million. Cash flow from operations was $26.7 million in Q4. Looking ahead, Assertio projects 2023 net product sales between $150 million and $160 million. The company is strategically focused on expanding its product offerings and enhancing its balance sheet.